高循环 HMGB1 表明接受化疗免疫治疗的晚期平滑肌肉瘤患者预后良好。
High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy.
机构信息
Equipe labellisée par La Ligue contre le cancer, Université de Paris Cité, Sorbonne Université, Paris, France.
Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France.
出版信息
Oncoimmunology. 2024 Dec 31;13(1):2432059. doi: 10.1080/2162402X.2024.2432059. Epub 2024 Nov 21.
Few clinical studies investigated the putative link between the activation of immunogenic cell death (ICD) and the oncological outcome. Recent data, published in a Phase 1b trial, demonstrated that an ICD-associated surge in the plasma concentration of high-mobility group box 1 (HMGB1) indicates favorable prognosis in patients with advanced leiomyosarcomas treated with the combination of doxorubicin, dacarbazine and nivolumab.
鲜有临床研究调查免疫原性细胞死亡（ICD）的激活与肿瘤学结果之间的潜在联系。最近发表的 1b 期临床试验数据表明，在接受多柔比星、达卡巴嗪和纳武利尤单抗联合治疗的晚期平滑肌肉瘤患者中，血浆高迁移率族蛋白 1（HMGB1）浓度的 ICD 相关激增预示着有利的预后。
Zotero 插件